Corvus Pharmaceuticals Inc (CRVS)

May 05, 2026

CRVS SEC FilingsCorvus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan

May 05, 2026

May 03, 2026

A Look At Corvus Pharmaceuticals (CRVS) Valuation After Adding Immunology Leader Dr. Andrew C. Chan To Its Board - Sahm

May 03, 2026

May 02, 2026

Could Corvus Pharmaceuticals’ (CRVS) New Board Appointment Reframe Its Immunology Strategy And Competitive Edge? - Sahm

May 02, 2026

May 02, 2026

MSN Money - MSN

May 02, 2026

May 01, 2026

Corvus Pharmaceuticals (CRVS.US) will release its earnings report after the market closes on May 7. - Moomoo

May 01, 2026

May 01, 2026

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

May 01, 2026

Apr 30, 2026

Corvus Pharmaceuticals (CRVS) to Release Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 29, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8.3%Here's Why - MarketBeat

Apr 29, 2026

Apr 28, 2026

CRVS stock surges 10%, hits 50-DMA for first time in a month – here’s why Goldman Sachs sees a 166% upside - MSN

Apr 28, 2026

Apr 27, 2026

Corvus Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo

Apr 27, 2026

Apr 27, 2026

Corvus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Chan Andrew C. - Moomoo

Apr 27, 2026

Apr 27, 2026

Corvus Pharmaceuticals (CRVS) director granted 30,000 stock options at $16.02 - Stock Titan

Apr 27, 2026

Apr 27, 2026

Corvus Pharmaceuticals (CRVS) director Andrew Chan files Form 3 - Stock Titan

Apr 27, 2026

Apr 27, 2026

BlackRock (NYSE: BLK) holds 5.39M shares of Corvus Pharmaceuticals (CRVS) - Stock Titan

Apr 27, 2026

Apr 27, 2026

Goldman Sachs initiates coverage of Corvus Pharmaceuticals (CRVS) with buy recommendation - MSN

Apr 27, 2026

Apr 27, 2026

Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight - GlobeNewswire Inc.

Apr 27, 2026

Apr 27, 2026

Corvus jumps as Goldman Sachs initiates at buy on lead asset - MSN

Apr 27, 2026

Apr 26, 2026

Corvus Pharma stock dips over 6% after-hours following best day ever — what went wrong? - MSN

Apr 26, 2026

Apr 25, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat

Apr 25, 2026

Apr 24, 2026

Is Corvus Pharmaceuticals (CRVS) Reframing Its Immunology Strategy With Soquelitinib’s Drug‑Free Remission Narrative? - Sahm

Apr 24, 2026

Apr 24, 2026

Corvus Pharmaceuticals (NASDAQ: CRVS) outlines 2026 virtual meeting and pay vote - Stock Titan

Apr 24, 2026

Apr 24, 2026

Corvus Pharmaceuticals appoints ex-Genentech executive to board By Investing.com - Investing.com India

Apr 24, 2026

Apr 23, 2026

Corvus Pharmaceuticals Announces Board Changes and New Director - TipRanks

Apr 23, 2026

Apr 23, 2026

New Corvus (NASDAQ: CRVS) director joins as Scott Morrison exits - Stock Titan

Apr 23, 2026

Apr 23, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 10.2%Here's Why - MarketBeat

Apr 23, 2026

Apr 23, 2026

Corvus Pharmaceuticals appoints ex-Genentech executive to board - Investing.com

Apr 23, 2026

Apr 23, 2026

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors - marketscreener.com

Apr 23, 2026

Apr 21, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 9.5%What's Next? - MarketBeat

Apr 21, 2026

Apr 21, 2026

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting - The Manila Times

Apr 21, 2026

Apr 21, 2026

Corvus spotlights eczema drug data, including late-breaker remission results - Stock Titan

Apr 21, 2026

Apr 20, 2026

Corvus (CRVS) Stock: Build a Position? (Smart Money Exits) 2026-04-20Social Momentum Signals - Cổng thông tin điện tử Tỉnh Sơn La

Apr 20, 2026

Apr 18, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded at The Goldman Sachs Group - MarketBeat

Apr 18, 2026

Apr 18, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm

Apr 18, 2026

Apr 18, 2026

This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Sahm

Apr 18, 2026

Apr 18, 2026

Crude Oil Tumbles 12%; State Street Posts Upbeat Earnings - Sahm

Apr 18, 2026

Apr 17, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap UpHere's What Happened - MarketBeat

Apr 17, 2026

Apr 17, 2026

Corvus jumps as Goldman Sachs initiates at Buy on lead asset - Seeking Alpha

Apr 17, 2026

Apr 17, 2026

Goldman Sachs Initiates Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $40 - 富途牛牛

Apr 17, 2026

Apr 17, 2026

Goldman Sachs initiates Corvus Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada

Apr 17, 2026

Apr 15, 2026

Corvus (CRVS) Stock Consolidates (On the Radar) 2026-04-15Micro Trends - UBND thành phố Hải Phòng

Apr 15, 2026

Apr 15, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 4.3%Should You Sell? - MarketBeat

Apr 15, 2026

Apr 14, 2026

CRVS Technical Analysis | Trend, Signals & Chart Patterns | CORVUS PHARMACEUTICALS INC (NASDAQ:CRVS) - ChartMill

Apr 14, 2026

Apr 13, 2026

Price Action: Is Corvus Pharmaceuticals Inc undervalued by DCF analysis2026 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN

Apr 12, 2026